IL6 and hepatocellular carcinoma: The second class (non-proliferation class) accounts for 50% of HCC and is similarly subdivided into two groups: one characterized by activation of the WNT/β-catenin signaling pathway because of frequent CTNNB1 mutations and the other (interferon subclass) with an activated IL6–JAK–STAT signaling pathway and a more inflamed tumor microenvironment with frequent TERT promoter mutations.